Verteporfin

Photoenhancer — SENSORY ORGANS

Key facts

Verteporfin is a drug in the Photoenhancer class catalogued in DrugCentral. It was first approved by the FDA in 2000. Its mechanism of action is classified as Photoabsorption. Recorded indications include Choroidal retinal neovascularization, Exudative age-related macular degeneration, Ocular histoplasmosis syndrome and Pathologic Myopia.

• Drug class: Photoenhancer.
• Mechanism of action: Photoabsorption.
• Indications: Choroidal retinal neovascularization, Exudative age-related macular degeneration, Ocular histoplasmosis syndrome and Pathologic Myopia.
• ATC code: S01LA01 (Antineovascularisation agents).
• Molecular formula: C82H84N8O16; molecular weight 1437.61 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

• Choroidal retinal neovascularization
• Exudative age-related macular degeneration
• Ocular histoplasmosis syndrome
• Pathologic Myopia

Contraindications (3)

• Breastfeeding (mother)
• Disease of liver
• Porphyria

Mechanism & targets

• Mechanism of action (MoA): Photoabsorption
• Established pharmacologic class: Photoenhancer

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2000-07-27	EMA	—	—
2000-04-12	FDA	—	VALEANT LUXEMBOURG

ATC classification

ATC code	Therapeutic hierarchy
S01LA01	SENSORY ORGANS › OPHTHALMOLOGICALS › OCULAR VASCULAR DISORDER AGENTS › Antineovascularisation agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Visual acuity reduced	1957.6
Retinal haemorrhage	1141.6
Choroidal neovascularisation	640.9
Polypoidal choroidal vasculopathy	575.0
Retinal pigment epithelial tear	467.7
Detachment of retinal pigment epithelium	425.9
Disease progression	396.5
Vitreous haemorrhage	309.3
Retinal detachment	295.3
Subretinal fluid	234.2
Retinal degeneration	218.0
Retinal oedema	209.6

Chemical structure

• Molecular formula: C₈₂H₈₄N₈O₁₆
• Molecular weight: 1437.61 g/mol
• CAS number: 129497-78-5
• InChIKey: —
• PubChem CID: 5362420

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Verteporfin used for?

DrugCentral lists the following indications for Verteporfin: Choroidal retinal neovascularization, Exudative age-related macular degeneration, Ocular histoplasmosis syndrome and Pathologic Myopia.

How does Verteporfin work?

Verteporfin is classified as Photoabsorption.

When was Verteporfin first approved?

Verteporfin was first approved by the FDA in 2000.

What drug class does Verteporfin belong to?

Verteporfin is in the Photoenhancer class.

What is the chemical formula of Verteporfin?

Verteporfin has the molecular formula C82H84N8O16 and a molecular weight of 1437.61 g/mol.

Sources

• DrugCentral drug card 2816 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL5314346 — compound record and bioactivity
• PubChem CID 5362420 — chemical identifiers
• DrugBank DB00460 — drug record
• FDA UNII 0X9PA28K43 — substance identity
• DailyMed: FDA labels for Verteporfin — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.